230 participants
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-02
- Start Date:
- 2023-05-16
- Completion:
- 2027-06-11
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
- DRUG
- BIOLOGICAL
No Results Yet